Cobalt(III) Schiff Base complexes stabilize non-fibrillar amyloid-β aggregates with reduced toxicity
Kaleigh F. RobertsiD, Christopher R. BrueiD, Anna Preston, Damonick Baxter, Emma Herzog, Eleni A. VarelasiD, Thomas J. MeadeiD
Abstract
The aggregation of A{beta} is believed to be foundational to the pathogenesis of Alzheimers disease (AD). In vitro aggregation kinetics have been shown to correlate with rates of disease progression in both AD patients and animal models, thus proving to be a useful metric for testing A{beta}-targeted therapeutics. Here we present evidence of Cobalt(III) Schiff base complex (Co(III)-sb) modulation of A{beta} aggregation kinetics by a variety of complementary techniques. These include Thioflavin T (ThT) fluorescence, circular dichroism (CD) spectroscopy, transmission electron microscopy (TEM), and atomic force microscopy (AFM). Our data was fitted to kinetic rate laws using a mathematical model developed by Knowles et al. in order to extract mechanistic information about the effect of Co(III)-sb on aggregation kinetics. Our analysis revealed that Co(III)-sb significantly decreases the kinetic parameter k+, and significantly increases the polymerization rate kn, suggesting that Co(III)-sb causes A{beta} to rapidly form stable oligomeric species that are unable to elongate into mature fibrils. This result was corroborated by TEM and AFM of A{beta} aggregates in vitro. We also demonstrate that A{beta} aggregate mixtures produced in the presence of Co(III)-sb exhibit decreased cytotoxicity compared to untreated samples. Statement of SignificanceAmyloid-{beta} is thought to be a key mediator in the pathology of Alzheimers disease, yet its precise mechanisms of toxicity are poorly understood. The interaction of A{beta} with endogenous metal ions via its N terminal Histidine residues has been shown to alter the peptides aggregation and toxicity. As such, metal-based complexes have been developed both as therapeutic agents as well as tools for investigating the role of metal binding in the pathogenesis of AD. This work expands on our previous studies developing Cobalt(III) Schiff base complexes as amyloid inhibitors. Here we demonstrate effective inhibition of aggregation by various complementary modalities. Additionally we show that Co(III)-sb reduces the toxicity of A{beta} aggregates to cells in culture.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 12
- FWCI
- 0.75
- Field percentile
- top 30%
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular Complexes for Effective Inhibition of Tau Aggregation
Nalini Vijay Gorantla, Vinod Gokulkrishna Landge, … Subashchandrabose Chinnathambi·bioRxiv·Jul 6, 2018
- Collagen hydrogel confinement of amyloid-β accelerates aggregation and reduces cytotoxic effects
L. Simpson, G. Szeto, … J. Leach·bioRxiv·Jul 23, 2019
- Melanin Suppresses Aβ Aggregation and Toxicity
Alexander Röntgen, Jan L Heise, … Zenon Toprakcioglu·bioRxiv·Sep 2, 2026
- Amyloid beta aggregation promoted by iron leads to neuronal loss in an ex vivo model of Alzheimer's disease
Sowmya Sunkara, Rahul Krishnamoorthy, … Gerd Leitinger·bioRxiv·Jul 11, 2025
- Redox reactivities of membrane-bound amyloid-β-Cu complexes and their targeting by metallothionein-3
Luciano Perez-Medina, Gabriele Meloni·Free Radical Biology and MedicinePeer-reviewed·Aug 23, 2025
- Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity
Arun Upadhyay, Deepak Chhangani, … Jeffrey N. Savas·Molecular NeurodegenerationPeer-reviewed·Sep 14, 2023